|
Vol. 10.46 – 24 November, 2021
|
|
|
|
|
|
Researchers showed that loss of ABHD5 promoted c-Met activation to sustain colorectal cancer stemness in a non-canonical manner.
[Nature Communications]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
Scientists assessed the role of the sulfiredoxin-peroxiredoxin redox system and mitochondrial oxidative phosphorylation in maintaining the stemness and survival of colon CSCs.
[Redox Biology]
|
|
|
|
|
The mechanism by which autophagy affects the self-renewal of CSCs remains unclear. Researchers investigated whether autophagy activation contributed to CSC properties of head and neck squamous cell carcinoma.
[Oncogene]
|
|
|
|
|
Scientists found that progestin resistance of endometrial CSCs could be improved or reversed by using in vitro fertilization (IVF)-generated embryonic sac-derived fluid containing the embryonic microenvironment.
[Cancer Letters]
|
|
|
|
|
The authors investigated whether transmembrane serine protease 4 (TMPRSS4) confered cancer stem–like properties to prostate cancer cells and characterized the underlying mechanisms.
[Journal of Experimental & Clinical Cancer Research]
|
|
|
|
|
Researchers tested the hypothesis that metabolic stress induced breast cancer stem-like cell phenotype in triple-negative breast cancer.
[British Journal of Cancer]
|
|
|
|
|
Circular RNA (circRNA) is a unique sort of non-coding RNAs and widely participate in the modulation of cancer progression. Investigators identified the critical function of circRNA circPIP5K1A in stemness of osteosarcoma cells.
[Journal of Translational Medicine]
|
|
|
|
|
Scientists examined the regulatory effects of tumor necrosis factor receptor-associated factor-binding protein domain (ZRANB1) on the maintenance of CSC properties and tumor growth in colorectal cancer.
[Cellular Signalling]
|
|
|
|
|
Secretome analysis was performed in pancreatic CSC-enriched spheres and controlled adherent cells for biomarker discovery.
[BMC Cancer]
|
|
|
|
|
|
|
Scientists summarize current clinical trials, which assessed the safety and efficacy of breast cancer stem cells-related therapies.
[Journal of Experimental & Clinical Cancer Research]
|
|
|
|
|
|
Biosplice Therapeutics, Inc. announced the dosing of the first subject in a Phase Ib, open-label, multicenter, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors.
[Biosplice Therapeutics, Inc.]
|
|
|
|
|
|
December 1 – 10, 2021
Virtual
|
|
|
|
|
|
|
Fred Hutchinson Cancer Research Center – Seattle, Washington, United States
|
|
|
|
|
Weill Cornell Medical College – New York, New York, United States
|
|
|
|
|
Oregon Health & Science University – Portland, Oregon, United States
|
|
|
|
|
St. Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|